Boston Scientific’s LUMINIZE RF Balloon Catheter shows promising results in AF-FICIENT I trial
Boston Scientific has announced that its LUMINIZE Radiofrequency (RF) Balloon Catheter, developed for isolating pulmonary veins (PVs) in atrial fibrillation (AF) treatment, has demonstrated positive ... Read More
Nordic Nanovector launches US Phase 2b trial for Betalutin in follicular lymphoma
Nordic Nanovector, a Norwegian biopharmaceutical company, has commenced the first clinical site in the United States for its PARADIGME trial. This pivotal trial is designed ... Read More
Quotient Sciences opens new $15m facility in Garnet Valley to boost drug development capabilities
Quotient Sciences, a UK-based drug development services provider, has inaugurated a new early phase formulation and manufacturing plant in Garnet Valley, Pennsylvania. The facility, spanning ... Read More
MaaT Pharma commences HERACLES Phase 2 trial for MaaT013 in battle against acute graft-versus-host disease
MaaT Pharma, a French oncology company, has announced a significant milestone in its clinical research: the dosing of the first patient in the HERACLES Phase ... Read More
Alkermes expands Phase 1 trial of ALKS 4230 in combination with KEYTRUDA for advanced solid tumors
Irish biopharmaceutical company Alkermes has announced an expansion of its ongoing Phase 1 trial to evaluate the safety and anti-tumor activity of its immuno-oncology drug ... Read More
PvP Biologics launches Phase 1 trials for celiac disease candidate Kuma062
PvP Biologics, a US-based pharmaceutical company, has recently begun two phase 1 clinical trials to assess the safety, tolerability, and pharmacodynamics of Kuma062, a promising ... Read More
Compugen initiates Phase 1 trial of COM701 cancer immunotherapy in advanced solid tumors
Israeli pharmaceutical company Compugen has announced the commencement of a phase 1 clinical trial for its innovative cancer immunotherapy antibody, COM701, targeting patients with advanced ... Read More
FDA declines approval for Sunovion’s ADHD drug dasotraline, citing need for more data
In a regulatory setback, the U.S. Food and Drug Administration (FDA) has decided not to approve Sunovion Pharmaceuticals’ dasotraline, a dual-acting dopamine and norepinephrine reuptake ... Read More
Kodiak Sciences completes enrollment for KSI-301 safety study in retinal disease
Kodiak Sciences, a California-based biotechnology company, has recently completed patient enrollment for a phase 1 safety and tolerability study of its innovative retinal disease drug, ... Read More
Pfizer ends clinical Trials of DMD drug domagrozumab after disappointing results
Pfizer, the US pharmaceutical giant, has announced the discontinuation of two ongoing clinical trials for its drug domagrozumab (PF-06252616), intended to treat Duchenne muscular dystrophy ... Read More